Journal
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
Volume 34, Issue 4-5, Pages 270-273Publisher
MASSON EDITEUR
DOI: 10.1016/j.gcb.2010.03.009
Keywords
-
Categories
Funding
- Swiss National Science Foundation
- Agence Nationale de la Recherche
- Ecole Polytechnique Federate de Lausanne
- FEBS
Ask authors/readers for more resources
Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease. (C) 2010 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
